Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

T-Cell and NK-Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
T-Cell and NK-Cell Neoplasm

Hematologic Malignancy

T-Cell and NK-Cell Neoplasm

CI-CAN-00001561Explore in graph →

HematologicNon-malignant268 active trials13 approved drugs18 evidence items

NCIt: C27908

Overview
Statistics
Survival
Genomics2
Variants & evidence18
Drugs7
Trials1103
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (13)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–13 of 13 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
· J Clin Oncol · 2017 · PMID 28787259 · validated civic_curation pubmed
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
· Genes Chromosomes Cancer · 2013 · PMID 23341344 · validated civic_curation pubmed
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
· Blood · 2012 · PMID 22215888 · validated civic_curation pubmed
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
· Nat Med · 2013 · PMID 23377281 · validated civic_curation pubmed
Somatic STAT3 mutations in large granular lymphocytic leukemia.
· N Engl J Med · 2012 · PMID 22591296 · validated civic_curation pubmed
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
· Lancet Oncol · 2013 · PMID 23598171 · validated civic_curation pubmed
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.
· Blood · 2015 · PMID 26268241 · validated civic_curation

Showing 1–13 of 13 publications

Crizotinib in anaplastic large-cell lymphoma.

· N Engl J Med · 2011 · PMID 21345110 · validated civic_curation pubmed

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

· Mol Genet Genomic Med · 2015 · PMID 25802883 · validated civic_curation pubmed

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

· Mol Cancer Ther · 2007 · PMID 18089725 · validated civic_curation pubmed

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

· Cancer Cell · 2012 · PMID 23079656 · validated civic_curation pubmed

Integrated molecular analysis of adult T cell leukemia/lymphoma.

· Nat Genet · 2015 · PMID 26437031 · validated civic_curation pubmed

William T et al. Blood Adv 2023

· 2023 · PMID 37078708 · validated cbioportal_study pubmed